GlassScriptPhysician profile
Marc L Ladenheim
NPI 1558363416
$14,892.35
in general payments reported to CMS, 2019-2025
56 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,311 · 2020: $1,222 · 2021: $1,656 · 2022: $1,454 · 2023: $6,993 · 2024: $1,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $5,535 · Food and Beverage: $2,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $5,535.35 |
| Food and Beverage | $2,714.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,544.41 | 2023-2024 | Avalus |
| Astrazeneca Pharmaceuticals LP | $1,034.30 | 2019-2024 | Farxiga, Brilinta |
| Novartis Pharmaceuticals Corporation | $925.60 | 2019-2024 | |
| Boston Scientific Corporation | $857.15 | 2019-2024 | Emblem Mri S-Icd, Bodyguardian, Lux-Dx Insertable Cardiac Monitor |
| Lilly USA, LLC | $763.96 | 2019-2024 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $593.51 | 2019-2024 | Jardiance, Tradjenta |
| Novo Nordisk INC | $468.05 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Cardiovascular Systems INC. | $454.97 | 2019 | |
| Abiomed | $396.40 | 2019 | |
| Pfizer INC. | $327.75 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $308.42 | 2021-2024 | |
| Amgen INC. | $282.86 | 2019-2024 | Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $271.74 | 2019-2024 | Eliquis, Camzyos |
| Glaxosmithkline, LLC. | $230.78 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $213.69 | 2019-2024 | Xarelto |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Ladenheim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.